Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 47 Cash-to-Debt is 0.09 as of Jun. 2026, which is 61% below its 10-year median of 0.23. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr47.05. The stock has 3 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 91.99% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Boule Diagnostics AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.09.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Boule Diagnostics ABcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Boule Diagnostics AB's Cash-to-Debt or its related term are showing as below:
CHIX:BOULs'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.23 Max: 1.52
Current: 0.09
During the past 13 years, Boule Diagnostics AB's highest Cash to Debt Ratio was 1.52. The lowest was 0.08. And the median was 0.23.
CHIX:BOULs's Cash-to-Debt is ranked worse than 91.99% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.69
vs CHIX:BOULs: 0.09
Boule Diagnostics AB (CHIX:BOULs) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Boule Diagnostics AB Cash-to-Debt Related Terms
Boule Diagnostics AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:BOULS vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a Cash-to-Debt of 0.09 as of Jun. 2026. This is 61% below median its historical median of 0.23. Over the past decade, Boule Diagnostics AB's Cash-to-Debt has ranged from 0.08 to 1.52. According to the industry distribution chart, Boule Diagnostics AB ranks #781 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 92%.
Is Boule Diagnostics AB's Cash-to-Debt too high?
Boule Diagnostics AB's current Cash-to-Debt of 0.09 is 61% below median its 10-year median of 0.23. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 1.52. The Medical Devices & Instruments industry median Cash-to-Debt is 1.69. Boule Diagnostics AB's value of 0.09 is 94.7% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #781 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #781 out of 849 companies for Cash-to-Debt. This places Boule Diagnostics AB in the lower half of its industry. The industry median Cash-to-Debt is 1.69. Boule Diagnostics AB's value of 0.09 is 94.7% below this benchmark. Historically, Boule Diagnostics AB's own Cash-to-Debt has ranged from 0.08 to 1.52 over the past decade. While the company's 10-year median is 0.23 vs. the industry median of 1.69, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.69, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Cash-to-Debt of 0.09 is 94.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Cash-to-Debt is 0.09, which is 61% below median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Cash-to-Debt of 0.09. The stock's GF Value™ is kr47.05, compared to a current price of kr26.30 — trading 44.1% below its estimated fair value. The current Cash-to-Debt is 0.09, which is 61% below median its 10-year median of 0.23 and 94.7% below the Medical Devices & Instruments industry median of 1.69. Boule Diagnostics AB's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Cash-to-Debt is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 44.1% below its estimated GF Value™ of kr47.05.
Key valuation signals for CHIX:BOULS:
Cash-to-Debt: 0.09 (61% below median its 10-year median of 0.23)
GF Value™: kr47.05 vs. price of kr26.30 (44.1% below fair value)
Industry Position: 94.7% below the Medical Devices & Instruments median (#781 of 849)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
